Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
11,357 total articles
Surf Air Mobility (SRFM) trades like a micro-cap with headline risk, but a meaningful commercial launch of SurfOS and a $100M strategic relationship with Palantir create a near-term path to revenue expansion. Market cap sits below $100M while EV is ~$140M and price-to-sales is 0.87x; for patient, risk-aware traders this is a directional long with d…
AEVEX (AVEX) is a newly public defense-tech firm building a full drone and autonomy stack for ISR and tactical missions. The IPO and recent rally put the stock into growth multiple territory, but strong institutional demand, a $3.22B market cap and visible contract leverage create an actionable mid-term long trade with defined risk controls.
We upgrade Xero to a buy for a mid-term swing: an AI partnership plus positive industry survey results create a clear catalyst path for subscription growth and monetization. Entry at $12.50, stop at $10.50, target $16.00 over roughly 45 trading days if execution and uptake track expectations.
Brookfield Corporation pairs hard assets with an emerging insurance and asset-management engine. At a $103.8B market cap and trading near $46.41, the stock offers asymmetric upside if management converts insurance float and AUM into high-margins and carried interest. This trade targets $65 with a $41 stop, sized for a long-term hold (180 trading da…
Albemarle sits at the center of a potential structural shift in lithium demand driven by utility-scale battery energy storage systems (BESS). With capacity discipline, asset sales and targeted reactivations, the company can convert improving lithium pricing into durable margins. This trade targets a mid-term move to $230 while protecting downside w…
Apple’s recent leadership changes look like continuity by another name: experienced insiders, an intact product roadmap and a capital return engine that keeps investors comfortable. This trade idea targets a measured long exposure with defined risk limits — capture upside from product and services momentum while protecting against execution and reg…
First Quantum Minerals (FQVLF) is a large copper producer ($22.5B market cap) trading well above 2025 lows but still below its January highs. A combination of improving copper fundamentals, operational resets, and an active short base creates an asymmetric swing trade. This idea lays out a specific entry, stop and target with horizon and risk contr…
Perma-Pipe (PPIH) has retraced from its 52-week high and is trading at a more attractive entry after strong backlog and Q1 recovery. Fundamentals show improving profitability (trailing EPS $2.10, ROE ~18.8%) and a modest leverage profile. This trade idea presents a measured long with defined entry, stop and target tailored to a mid-term horizon.
American Water Works (AWK) is a high-quality regulated utility trading below prior highs after a period of weak technical momentum and merger uncertainty. With 2026 EPS guidance at $6.02-$6.12, a 7-9% long-term growth target, and an ongoing merger with Essential Utilities plus an accretive acquisition pipeline, the risk/reward at $131.45 is attract…
NAN offers a monthly tax-exempt distribution (annualized yield ~7.58%) and is trading inside a tight 52-week range. Technicals and income make a case for a mid-term long trade with defined entry, stop and target levels.
Zions Bancorporation is showing the building blocks for a 2026 re-rating: rising yields should lift net interest income, recent corporate actions (a $75M repurchase and steady dividend) support per-share cash flow, and the stock trades at a modest P/E and low P/B. We lay out a long trade with entry at $62.00, stop at $57.00 and a primary target of …
Intuitive Machines (LUNR) is trading near $28.41 after a run from a $6.75 52-week low as investor focus shifts from a single lunar mission to recurring cislunar services. The company shows early revenue upside via government and commercial lunar contracts (including a $180.4 million award), strong liquidity per share, but valuation metrics (P/S ~20…
Abbott Laboratories (ABT) is trading near its 52-week low at $93.71 while still generating strong free cash flow and paying a $0.63 quarterly dividend (2.5% yield). A combination of an earnings-guidance reset, acquisition-related dilution fears, and macro volatility pushed the stock lower. Fundamentals—$11.16B in Q1 revenue, solid device and diabet…
Netflix's latest U.S. price increases and continued ad monetization give the company clear levers to protect margins and FCF. The stock pulled back after guidance conservatism; that creates a tactical buying window for disciplined traders who want exposure to durable streaming economics. Trade plan: enter $92.00, stop $80.00, target $110.00, mid te…
Bright Horizons (BFAM) looks positioned for a re-rating. At roughly $85, the stock trades at ~24x earnings with $258M in trailing free cash flow and an enterprise value near $5.5B. Improving technicals, manageable leverage and reopening tailwinds create a clear risk-reward for a mid-term trade targeting $110 over the next 45 trading days, with a $7…
Tesla looks richly valued on traditional metrics, trading near its 50-day average with modest technical setup and heavy short activity. Given elevated expectations and the company's huge market cap, a muted post-earnings price reaction is a plausible outcome. This idea outlines a short-term short-into-strength trade: enter on a rally, keep a tight …
Occidental Petroleum (OXY) has pulled back from recent highs after a brief oil reprieve. The company still generates meaningful free cash flow, trades at a reasonable enterprise multiple, and just posted a high-impact Gulf discovery that can re-price the story if oil stays resilient. This trade idea sets an exact entry, stop and target for a mid-te…
Pinterest has traded down from its 52-week highs as ad-revenue worries, tariff chatter and multiple securities filings dominated headlines. The stock now offers a mid-term contrarian entry around $20.50 with defined risk, supported by positive free cash flow, reasonable valuation metrics and improving technical momentum. This is not a no-risk trade…
Spotify has shifted from pure music streaming to a data-rich platform that can monetize podcasts, video, and personalized ad formats. Recent earnings and product moves suggest durable margin expansion and an accelerating monetization runway. This trade uses a measured long entry with a clear stop and a 180-trading-day target to capture the next leg…
Apple slid after Tim Cook's announced transition to executive chairman and John Ternus's promotion to CEO. The move is meaningful politically and operationally, but Apple’s scale, cash generation and product moat remain intact. This trade idea outlines a mid-term swing entry at $267.00 with a $295.00 target and a $255.00 stop — a risk/reward setup …
We expect the US dollar to face cyclical pressure over the coming weeks to months. Tactical longs in EUR/USD and AUD/USD and a short on the DXY offer asymmetric risk-reward if US yields soften and external growth momentum reasserts. The plan below includes exact entries, stops and targets with horizon guidance and clear risk points.
Compass Pathways (CMPS) is a beaten-down biotech turned momentum leader after regulatory acceleration and positive Phase 3 data for COMP360. The stock is richly priced for a biotech but fundamentals and market structure (heavy short interest and large short volume on 04/20/2026) create a tactical long opportunity. This trade idea lays out entry, st…
Equity Bancshares (EQBK) looks like a pragmatic buy here: the stock sits below $1 billion market cap, generates meaningful free cash flow, and has a recent history of earnings beats and targeted M&A. Valuation metrics are not demanding on a price-to-book basis, short interest is elevated, and technicals are neutral-to-bullish. This trade lays out a…
BridgeBio (BBIO) is staging a transition from a pure rare-disease developer to a commercial-stage company with optionality for oncology expansion. Recent wins (Attruby long-term mortality data, positive BBP-418 Phase 3 readout, achondroplasia data) should drive revenue and M&A firepower that could be redeployed into KRAS-targeted assets or partners…
Valero’s refining cash flow has surged amid diesel and gasoline spikes, producing free cash flow of roughly $3.7B and a balance sheet that supports outsized capital returns. With the stock trading near $229, we outline a mid-term long trade designed to capture roughly 14% upside to $261 while protecting capital with a $215 stop.
